Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

In addition, the company just acquired Ambry Genetics for hereditary cancer tests helping Tempus AI expand into other areas such as rare disorder, pediatrics and cardiology. Tempus AI recently ...

Growth is forecast to continue in the 23-25% range in eFY25. Tempus is expecting to close the Ambry acquisition in Q1 2025. The deal will be accretive to Tempus' adjusted EBITDA margin while ...

KUALA LUMPUR: Asean has the potential to become a 'middle power', which is a power that can play an important role in dealing with tensions between great powers, not with the aim of war, but as a ...

Mackenzie Schuessler is an MA student at George Mason University, working towards a graduate degree in International Security. Additionally, she is the Program Administrator for the Nuclear Policy ...